Clinical trials of resveratrol

An expanding body of preclinical evidence suggests resveratrol has the potential to impact a variety of human diseases. To translate encouraging experimental findings into human benefits, information is first needed on the safety, pharmacokinetics, pharmacodynamics, and, ultimately, clinical efficacy of resveratrol. Published clinical trials have largely focused on characterizing the pharmacokinetics and metabolism of resveratrol. Recent studies have also evaluated safety and potential mechanisms of activity following multiple dosing, and have found resveratrol to be safe and reasonably well‐tolerated at doses of up to 5 g/day. However, the occurrence of mild to moderate side effects is likely to limit the doses employed in future trials to significantly less than this amount. This review describes the available clinical data, outlines how it supports the continuing development of resveratrol, and suggests what additional information is needed to increase the chances of success in future clinical trials.

[1]  T. Key.  Diet, insulin-like growth factor-1 and cancer risk , 2011, Proceedings of the Nutrition Society.

[2]  R. Lamuela-Raventós,et al.  Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. , 2006, Clinical chemistry.

[3]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[4]  E. Chevet,et al.  Loss of Tumorigenicity and Metastatic Potential in Carcinoma Cells Expressing the Extracellular Domain of the Type 1 Insulin-Like Growth Factor Receptor , 2004, Cancer Research.

[5]  P. Maliakal,et al.  Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. , 2004, Journal of agricultural and food chemistry.

[6]  A. Desmoulière,et al.  Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. , 2003, Life sciences.

[7]  A. Falcão,et al.  Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. , 2009, Molecular nutrition & food research.

[8]  K. Brown,et al.  Development of Dietary Phytochemical Chemopreventive Agents: Biomarkers and Choice of Dose for Early Clinical Trials , 2009, Cancer Prevention Research.

[9]  Donald J L Jones,et al.  Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. , 2010, Cancer research.

[10]  Ananda Sen,et al.  Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. , 2010, Cancer research.

[11]  V. Somoza,et al.  Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. , 2008, Molecular nutrition & food research.

[12]  R. Lamuela-Raventós,et al.  Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. , 2005, Analytical chemistry.

[13]  D. Hanahan,et al.  Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. , 2002, Cancer cell.

[14]  J. Crowell,et al.  Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent , 2007, Cancer Epidemiology Biomarkers & Prevention.

[15]  J. Pezzuto,et al.  Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. , 2010, Journal of medicinal chemistry.

[16]  A. Gescher,et al.  Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  Jessica A. Miller,et al.  Resveratrol Modulates Drug- and Carcinogen-Metabolizing Enzymes in a Healthy Volunteer Study , 2010, Cancer Prevention Research.

[18]  D. Kennedy,et al.  Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. , 2010, The American journal of clinical nutrition.

[19]  A. Falcão,et al.  Pharmacokinetics of Trans‐resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects , 2009, Journal of clinical pharmacology.

[20]  R. Lamuela-Raventós,et al.  Matrix effects on the bioavailability of resveratrol in humans , 2010 .

[21]  D. Yee,et al.  Insulin-like growth factor-I and cancer risk. , 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[22]  R. Marchelli,et al.  Bioavailability of trans-resveratrol from red wine in humans. , 2005, Molecular nutrition & food research.

[23]  T. Walle,et al.  HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS , 2004, Drug Metabolism and Disposition.

[24]  R. Baxter,et al.  The IGF axis and programmed cell death , 1999, Immunology and cell biology.

[25]  A. Heredia,et al.  Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. , 2004, Journal of pharmaceutical sciences.

[26]  J. Pezzuto,et al.  Pleiotropic mechanisms facilitated by resveratrol and its metabolites. , 2010, The Biochemical journal.

[27]  D. Dunger,et al.  Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. , 2002, Journal of the National Cancer Institute.

[28]  D. Goldberg,et al.  Absorption of three wine-related polyphenols in three different matrices by healthy subjects. , 2003, Clinical biochemistry.

[29]  V. Somoza,et al.  Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. , 2005, Molecular nutrition & food research.